Pragma Bio
Pragma Bio discovers microbiome-based therapies and biomarkers to improve outcomes for cancer and autoimmune patients. The company combines genomic sequencing, artificial intelligence, and synthetic biology in a biotechnology platform that aggregates public and private microbiome datasets to generate a searchable microbiome database. Its analytics identify multi-layered biological signatures and novel biomarkers to risk-stratify patients and predict clinical outcomes. The platform supports discovery of natural-chemistry therapeutics and preclinical candidates for immunological disorders. Pragma Bio primarily partners with biopharma and clinical researchers to translate discoveries toward clinical development.
Pragma Bio
Pragma Bio discovers microbiome-based therapies and biomarkers to improve outcomes for cancer and autoimmune patients. The company combines genomic sequencing, artificial intelligence, and synthetic biology in a biotechnology platform that aggregates public and private microbiome datasets to generate a searchable microbiome database. Its analytics identify multi-layered biological signatures and novel biomarkers to risk-stratify patients and predict clinical outcomes. The platform supports discovery of natural-chemistry therapeutics and preclinical candidates for immunological disorders. Pragma Bio primarily partners with biopharma and clinical researchers to translate discoveries toward clinical development.
TL;DR
Focus: Microbiome-based therapies and biomarkers for cancer and autoimmune indications
Platform: AI-enabled biology-first platform (PIKASO) combining bioinformatics, synthetic biology, and medchem
Founded: 2018–2019 (company origins reported 2018; snapshot lists 2019)
HQ: San Francisco Bay Area (South San Francisco / Millbrae area)
Recent financing: Series A announced Mar 2023 (reported ~$10M)
Company Overview
Problem Domain
Therapeutics and biomarker discovery at the intersection of microbiome biology and immunology (cancer, autoimmune, immune-related indications).
Founded
2019
Industry
Biotechnology
Tech Stack
Funding Track Record
10000000
Reported Series A announced March 22, 2023 (TechCrunch reported ~$10M)
Investor Signal
“Backed by venture and strategic investors including The Venture Collective, Viking Global Investors, Merck Global Health Innovation Fund, Iaso Ventures, Good AI Capital, CJ Investment”